Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
作者信息
Laupacis Andreas
机构信息
Institute for Clinical Evaluative Sciences, Toronto, ON.
出版信息
CMAJ. 2002 Jan 8;166(1):44-7.
Abstract
摘要
相似文献
1
Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
CMAJ. 2002 Jan 8;166(1):44-7.
2
3
Should cost-effectiveness take the blame?
CMAJ. 2003 Jun 10;168(12):1528; author reply 1528-9.
4
Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Issue Brief (Commonw Fund). 2009 Jul;60:1-13.
5
Role of budget impact in drug reimbursement decisions.
J Health Polit Policy Law. 2008 Apr;33(2):225-47. doi: 10.1215/03616878-2007-054.
6
How complete are drug history profiles that are based on public drug benefit claims?
Can J Clin Pharmacol. 2008 Winter;15(1):e108-16. Epub 2008 Feb 19.
7
Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
Can J Clin Pharmacol. 2002 Summer;9(2):79-99.
8
Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
Aust Health Rev. 2001;24(2):7-14. doi: 10.1071/ah010007.
9
Drug utilization: using objective data to achieve cost-efficiency.
Benefits Q. 2005;21(1):7-13.
10
The value of pharmaceuticals--some direction for employers.
Empl Benefits J. 2002 Sep;27(3):31-5.
引用本文的文献
1
A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making.
PLoS One. 2018 Nov 9;13(11):e0207410. doi: 10.1371/journal.pone.0207410. eCollection 2018.
2
Economic analysis of insulin initiation by pharmacists in a Canadian setting: The RxING study.
Can Pharm J (Ott). 2016 May;149(3):130-7. doi: 10.1177/1715163516640813. Epub 2016 Apr 5.
3
Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index.
Med Decis Making. 2016 Feb;36(2):264-74. doi: 10.1177/0272989X15599546. Epub 2015 Aug 27.
4
Adherence to prescribing recommendations made on a provincial formulary.
Healthc Policy. 2014 May;9(4):20-30.
5
Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery.
BMC Med Ethics. 2010 Aug 26;11:14. doi: 10.1186/1472-6939-11-14.
6
Tough choices: private sale of drugs in public hospitals.
CMAJ. 2010 Mar 9;182(4):374-6. doi: 10.1503/cmaj.081137. Epub 2010 Feb 8.
7
Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.
Pharmacoeconomics. 2010;28(3):175-84. doi: 10.2165/11530650-000000000-00000.
8
Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.
Healthc Policy. 2007 Nov;3(2):e128-44.
9
Engaging the public in priority-setting for health technology assessment: findings from a citizens' jury.
Health Expect. 2008 Sep;11(3):282-93. doi: 10.1111/j.1369-7625.2008.00501.x.
10
Building bridges between academic research and policy formulation: when costing less means costing more.
Pharmacoeconomics. 2007;25(6):523-8; author reply 528-32. doi: 10.2165/00019053-200725060-00007.
本文引用的文献
1
The heartbreak of drug pricing.
Ann Intern Med. 2001 Jun 5;134(11):1068-71. doi: 10.7326/0003-4819-134-11-200106050-00014.
2
Pharmaceutical price controls and patient welfare.
Ann Intern Med. 2001 Jun 5;134(11):1060-4. doi: 10.7326/0003-4819-134-11-200106050-00012.
3
Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.
Pharmacoeconomics. 1993 May;3(5):354-61. doi: 10.2165/00019053-199303050-00003.
4
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3.
5
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
JAMA. 1996;276(16):1339-41. doi: 10.1001/jama.276.16.1339.
6
Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
JAMA. 1996 Oct 16;276(15):1253-8.
7
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
JAMA. 1996 Oct 9;276(14):1172-7.
8
A study of the quality of life and cost-utility of renal transplantation.
Kidney Int. 1996 Jul;50(1):235-42. doi: 10.1038/ki.1996.307.
9
Zotero 插件